

****New release March 2010****

MarketVIEW: *Staphylococcus aureus* vaccines (CAT: VAMV002)

Proposal No/#PO	:	[Enter client specific #PO]
Product Name	:	MarketVIEW: <i>Staphylococcus aureus</i> vaccines – Global market forecast
Project Initiation Date	:	n/a
Billable days	:	n/a
Initiator(s)	:	[Enter client name, function and address]
Therapeutic Area	:	Nosocomial vaccines
Product (if applicable)	:	CAT No: VAMV002, published March 2010

Background

Staphylococcus aureus (*S.aureus*) is an opportunistic pathogen and a major cause of patient morbidity and mortality, especially in “at risk” populations. The organism can cause a wide range of infections ranging from mild skin infections to life-threatening bloodstream infections and pneumonia. MRSA-VAP (ventilator associated pneumonia) is now the most common invasive infection reported in US ICUs (National Healthcare Safety Network Figures) NHSN¹.

Prophylactic vaccines could prevent *S.aureus* infections and become cost effective in achieving savings from expensive infection control interventions e.g. MRSA screening on admission. Although all major companies have now announced *S.aureus* vaccine programs, Merck & Co (Intercell AG) are the most advanced (Phase II/III). If successful Merck & Co (Intercell AG) are predicted to be first to market in 2013/2014 potentially defining a highly lucrative new market category estimated by this analysis to range up to ~\$3 billion/yr at peak demand (HI SCENARIO).

This **MarketVIEW** product gives a comprehensive vaccine value (\$USD/volume (000s) forecast within target nosocomial populations until 2030. The model includes **LO/BASE/HI** forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on nosocomial vaccines.

¹ Hidron AI et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. *Infect Control Hosp Epidemiol.* 2008 Nov;29(11):996-1011.

Methodology

Using currently available information regarding the profile and predicted deployment of *S.aureus* prophylactic vaccines **VacZine Analytics** has modelled three potential global vaccine demand scenarios (mio doses) and revenue estimates (\$ 000s) based upon detailed analysis of “at risk” target populations across major Western markets. The provided model also gives estimates of market share per major development company and includes adjustable inputs of vaccine penetration, number of doses and pricing.

VacZine Analytics has closely monitored all significant source material pertaining to *S.aureus* epidemiology/vaccines. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the nosocomial field has also been utilised.

PRODUCT CONTENTS:

Published March 2010 (CAT No: VAMV002)

****This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

Executive Summary
Commercial model – key outputs
Total global predicted demand (doses, all scenarios)
Total global available market (\$000s all scenarios)
Total global available market, base case (\$ 000s)
Total available volume per vaccine segment, US – 2021
Company revenue summary
Commercial model – key assumptions
The role of *S.aureus* vaccine
Markets included in model
Population segments included in model
Population segments – low case
Population segments – base case
Population segments – hi case
Overall commercial model assumptions per scenario
Overall commercial model assumptions per country
Competitive situations
Merck/Intercell V710: estimated filing dates per indication
Methodology – general comments
Methodology and source inputs US
References
Disclaimer
About **VacZine Analytics**

PAGES: 30 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title sheet
Competitor summary
TOTAL CHARTS – forecast to 2030
CHARTS VALUE – HIGH
CHARTS VALUE – BASE
CHARTS VALUE – LO
CHARTS VOLUME – HIGH
CHARTS VOLUME – BASE
CHARTS VOLUME – LO
VALUE SUMMARY (TOTAL MARKET)
VOLUME SUMMARY (TOTAL MARKET)
US (all scenarios LO/BASE/HIGH)
Canada
UK
Germany
France
Spain
Italy
EU – other
Australia
Japan
Country target populations – forecast to 2030
Source material
ABCs report (US)
Hospital admissions (US)
Mechanical ventilations (US)
ICU pathogens (US)
US volume segment analysis
Back page
About VacZine Analytics
Disclaimer

WORKSHEETS: 65

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- o USD \$7995.00/ GBP £5395.00 (Region license)*


*A region is North America, Europe or ROW

For orders in the UK, VAT at 17.5% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according to the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009